Fortress Biotech (FBIO) and its majority-owned subsidiary, Cyprium Therapeutics announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $205M upon the closing of the transaction. In December 2023, Sentynl Therapeutics assumed full responsibility for the development and commercialization of ZYCUBO from Cyprium. The PRV was issued upon approval of ZYCUBO by the U.S. Food and Drug Administration on January 12, 2 ...

ATX-04 is a selective β2-adrenergic agonist with human proof-of-concept data demonstrating improved muscle function and enhanced response to enzyme replacement therapy MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for rare and neurologic diseases, today announced that it has entered into an exclusive worldwide license agreement with Duke University fo ...

Core Insights - Cigna Group reported fourth-quarter 2025 adjusted EPS of $8.08, exceeding estimates by 2.7% and reflecting a 22% year-over-year increase [1][9] - Adjusted revenues reached $72.5 billion, a 10% year-over-year rise, surpassing consensus estimates by 3.7% [1][9] Financial Performance - The Evernorth Health Services segment significantly contributed to quarterly results, driven by new business and client relationship expansion, alongside strong performance in Pharmacy Benefit Services and improved specialty volumes [2][5] - Cigna's medical customer base stood at 18.1 million, a decline of 5.4% year-over-year, impacted by divestitures to Health Care Services Corporation (HCSC) [3] - Total benefits and expenses increased by 10% year-over-year to $70.1 billion, primarily due to higher pharmacy and service costs [4] - Adjusted income from operations was $2.1 billion, up 16% year-over-year, benefiting from improved contributions from Cigna Healthcare and Evernorth Health Services [4] Segment Performance - Evernorth Health Services recorded revenues of $63.1 billion, a 17% year-over-year increase, exceeding estimates of $59.2 billion [5] - Cigna Healthcare's revenues fell 16% year-over-year to $11.1 billion, although it beat estimates by 2.1% [6] - Adjusted operating income for Cigna Healthcare surged 44% year-over-year to $734 million, despite missing consensus estimates by 2.7% [7] Financial Position - As of December 31, 2025, Cigna had cash and cash equivalents of $7.7 billion, a 1.7% increase from the previous year [8] - Total assets rose to $157.9 billion from $155.9 billion at the end of 2024 [8] - Long-term debt increased by 6.7% to $30.9 billion, while total equity grew by 1.5% to $41.9 billion [10] Capital Deployment - Cigna repurchased shares worth approximately $3.6 billion in 2025 [11] 2026 Outlook - Adjusted EPS is projected to be at least $30.25, indicating a minimum growth of 1.4% from 2025 [12] - Adjusted revenues are expected to reach around $280 billion, reflecting a 1.9% improvement from 2025 [13] - The adjusted SG&A expense ratio is estimated to be around 5% [13]

Core Insights - Elevance Health, Inc. (ELV) reported Q4 2025 adjusted EPS of $3.33, exceeding the Zacks Consensus Estimate by 7.3% and reflecting a 3.1% year-over-year increase [2] - Operating revenues increased by 9.6% year over year to $49.3 billion, although this figure fell short of consensus estimates by 0.5% [2] Financial Performance - The quarterly earnings were bolstered by strong premium growth, with premiums totaling $40.7 billion, a 12.3% year-over-year increase [5][10] - The Carelon division experienced a significant revenue increase of 27% year over year, reaching $18.7 billion, driven by acquisitions and scaling risk-based services [10][11] - Health Benefits segment revenues rose 11% year over year to $41.8 billion, surpassing estimates [8] Membership and Enrollment - Medical membership stood at approximately 45.2 million as of December 31, 2025, a decline of 1.1% year over year, primarily due to a drop in Medicaid membership [4] - Medicare Advantage membership growth partially offset the decline in overall medical membership [4] Expenses and Margins - Total expenses increased by 10.5% year over year to $49.5 billion, exceeding estimates [6] - The adjusted operating margin deteriorated by 110 basis points year over year to 0.8% [6] Cash Flow and Capital Deployment - Elevance Health reported cash and cash equivalents of $9.5 billion, a 14.5% increase from the end of 2024 [13] - The company generated net cash flow from operations of $4.3 billion in 2025, a decline of 26.1% from the previous year [14] - Share buybacks amounted to $471 million in Q4, with a remaining capacity of approximately $6.7 billion [15] Full-Year Results and Outlook - For the full year 2025, revenues reached $197.6 billion, up from $175.2 billion in 2024, driven by increased premium yields [16] - The company anticipates adjusted EPS for 2026 to be at least $25.50, indicating a 15.8% decline from 2025 [17] - Operating revenues are expected to see a low-single digit decline in 2026, with medical enrollment projected between 43.2 million and 43.9 million [18]

Core Insights - Centene Corporation (CNC) is expanding its supportive care services in Ohio through a partnership with Tuesday Health, launching on January 1, 2026, to provide structured palliative care for members with serious illnesses [1][4] Group 1: Partnership and Services - The program will offer eligible Buckeye members support from a diverse team including nurses, social workers, nurse practitioners, and physicians, aiming to manage symptoms and assist caregivers [2] - The initiative is designed to provide 24/7 access to clinicians, addressing issues early to prevent unnecessary hospital admissions [2][3] Group 2: Market Context and Strategy - The partnership is timely as Ohio faces increasing caregiver strain and a growing population with complex medical needs, with palliative care focusing on comfort and coordination [3] - This initiative aligns with CNC's value-based care strategy, particularly relevant for Medicaid, Medicare Advantage, and dual-eligible populations that typically incur higher medical costs [4] Group 3: Future Implications - The Ohio rollout creates a scalable framework for potential expansion of similar partnerships across other states if performance metrics are met [5] - While the immediate financial impact may be limited, this initiative could enhance the company's role in whole-person care and its commitment to managing complex populations [5] Group 4: Stock Performance - Over the past three months, CNC shares have increased by 23.8%, contrasting with a 6.8% decline in the industry [6]

Core Insights - Journey Medical Corporation announced successful results from a Phase 1 clinical trial for Emrosi, indicating it can be safely used for up to 16 weeks without significant safety issues [1][2] - Emrosi is FDA-approved for treating inflammatory lesions of rosacea in adults, with a focus on maintaining normal microbiota and avoiding antibiotic resistance [2][5] Company Overview - Journey Medical Corporation is a commercial-stage pharmaceutical company focused on marketing FDA-approved prescription products for dermatological conditions [8] - The company currently markets eight branded FDA-approved prescription drugs aimed at treating common skin conditions [8] Clinical Trial Details - The Phase 1 clinical trial (DFD-29-CD-006) was a multicenter, randomized, double-blind, placebo-controlled study involving 60 healthy adults [2] - The trial achieved all primary microbiological endpoints, showing no significant changes in skin, gastrointestinal, or vaginal microbiota [5] - No significant safety issues were reported during the study, reinforcing the treatment's tolerability [2][5] Rosacea Background - Rosacea is a chronic inflammatory skin condition affecting over 16 million Americans and approximately 415 million people worldwide [3] - The condition significantly impacts patients' self-confidence and social interactions, with many reporting adverse effects on professional life [3]

Core Insights - Armata Pharmaceuticals reported a quarterly loss of $0.42 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.15 per share a year ago [1] - The company posted revenues of $1.16 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 16.01%, and down from $2.97 million year-over-year [2] - The stock has increased approximately 264.9% since the beginning of the year, significantly outperforming the S&P 500's gain of 16.4% [3] Financial Performance - The company has surpassed consensus EPS estimates three times over the last four quarters [1] - The current consensus EPS estimate for the upcoming quarter is -$0.41 on revenues of $1.47 million, and for the current fiscal year, it is -$1.46 on revenues of $5.5 million [7] Market Outlook - The earnings outlook and management's commentary during the earnings call will be crucial for the stock's immediate price movement [3][4] - The Zacks Rank for Armata Pharmaceuticals is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry is currently in the top 34% of over 250 Zacks industries, suggesting a favorable environment for stocks within this sector [8] - Another company in the same industry, Fortress Biotech, is expected to report a quarterly loss of $0.43 per share, with revenues projected to be $23.68 million, reflecting a year-over-year increase of 61.9% [9]

Company Performance - Kamada reported quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.10 per share, but showing an increase from $0.07 per share a year ago, resulting in an earnings surprise of -10.00% [1] - The company posted revenues of $47.01 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.64% and increasing from $41.74 million year-over-year [2] - Over the last four quarters, Kamada has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Outlook - Kamada shares have increased approximately 9.4% since the beginning of the year, compared to the S&P 500's gain of 14.4% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for investors [4] - The current consensus EPS estimate for the coming quarter is $0.11 on revenues of $45.85 million, and for the current fiscal year, it is $0.39 on revenues of $180.87 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Kamada belongs, is currently in the top 36% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Kamada's stock performance [5][6]

Core Insights - Prothena reported a quarterly loss of $0.67 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.60, but an improvement from a loss of $1.10 per share a year ago, indicating an earnings surprise of -11.67% [1] - The company generated revenues of $2.42 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 90.26%, compared to revenues of $0.97 million in the same quarter last year [2] - Prothena's shares have declined approximately 25.9% year-to-date, contrasting with the S&P 500's gain of 15.6% [3] Future Outlook - The future performance of Prothena's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - The current consensus EPS estimate for the upcoming quarter is -$0.42 on revenues of $36.25 million, and for the current fiscal year, it is -$4.45 on revenues of $38.26 million [7] - The Zacks Industry Rank places the Medical - Biomedical and Genetics sector in the top 41% of over 250 Zacks industries, suggesting a favorable industry outlook [8] Estimate Revisions - Prior to the earnings release, the estimate revisions trend for Prothena was favorable, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expectations of outperforming the market in the near future [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Viewpoint - Avenue Therapeutics has announced the acquisition of its subsidiary Baergic Bio by Axsome Therapeutics, which includes the global rights to BAER-101, a novel therapy for epilepsy, potentially enhancing treatment options in a field with high unmet needs [1][2][7]. Company Overview - Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on developing therapies for neurologic diseases, headquartered in Miami, FL, and founded by Fortress Biotech, Inc. [5]. Transaction Details - The acquisition involves Axsome obtaining worldwide commercial, development, and manufacturing rights to BAER-101, with Baergic shareholders eligible for up to approximately $82 million in potential payments, including a $0.3 million upfront payment and milestone payments based on development and sales achievements [1][7]. - Avenue expects to receive approximately 74% of all future payments and royalties under the agreement [7]. Product Information - BAER-101, now referred to as AXS-17 by Axsome, has shown a promising safety and tolerability profile in clinical studies involving over 700 patients and is being evaluated for its anti-convulsant effects in epilepsy [3][2].